Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only
      Prescribing Information
      BOTOX® SMPC
      RESOURCES

      Contact us

      Please complete the form below and a member of the BOTOX® (botulinum toxin type A) team will get back to you.

      Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

       

      BOTOX® is indicated for the symptomatic treatment of focal spasticity, including:1

      • upper limb spasticity in adults 
      • ankle and foot disability due to lower limb spasticity in adults

      The BOTOX® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page. 

      Please enter First name
      Please enter Last name
      E-mail address is not valid
      Please enter Hospital name
      Please enter Hospital postcode

      Please select the items you are interested in:

      Please select one field.
      Please select one field.


      Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

      *Denotes mandatory field

      Incorrect. Please try again.

       

      References

      1. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed September 2024

       

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

       

      References

      1. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed September 2024

       

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      Date of preparation: September 2024. UK-BTX-240024.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.